Jie Cao

Jie Cao


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MSMeng Sha
Meng Sha
SJSeogsong Jeong
Seogsong Jeong
XWXin Wang
Xin Wang
YTYing Tong
Ying Tong
JCJie Cao
Jie Cao
QXQiang Xia
Qiang Xia
Tumor-associated lymphangiogenesis is considered significant in number of solid malignancies. However, its impact on prognosis of intrahepatic cholangiocarcinoma (ICC) after resection remains further confirmation. Herein, we conducted this study to evaluate prognostic impact of tumor-associated lymphangiogenesis in patients with ICC. Extent of tumor-associated lymphangiogenesis of ICC was evaluated by quantifying microlymphatic vessel density (MLVD) from immunohistochemical staining of a lymphatic endothelial-specific antibody (podoplanin). Clinicopathological characteristics were comprehensively analyzed to identify MLVD-associated factors. The patients were stratified into high and low MLVD groups according to the distinctive correlation between the MLVD and overall survival using the Spearman’s correlation test. Kaplan-Meier estimation was performed to confirm prognostic impact of MLVD in patients with ICC. Univariate and multivariate analyses were performed using the Cox proportional hazard model. The MLVD between 4 to 12 counts showed inverse proportion to the overall survival (Spearman’s r = − 0.66; 95% confidence interval [CI], − 0.82 to − 0.39; p < 0.0001), which was set as a cut-off for the high MLVD group, whereas the MLVD between 13 to 25 showed no correlation to the overall survival (r = − 0.11; 95% CI, − 0.38 to 0.19; p = 0.4791). The high MLVD group showed more frequent lymph node metastasis (p < 0.001) and were more likely to suffer from recurrence of the tumor compared to the low MLVD group (p < 0.001). The high MLVD was found to be independently associated with reduced overall and recurrence-free survival. The 5-year overall survival of the patients with high MLVD was significantly lower compared to those with low MLVD (0% vs 48%). Our study reveals that tumor-associated lymphangiogenesis is significantly associated with increased lymphatic metastasis, recurrence of the tumor, and reduced overall survival in patients with ICC, thus providing guidance when estimating postresection prognosis.

7 June 2025 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
MSMeng Sha
Meng Sha
JZJiang Zhang
Jiang Zhang
JLJin-Kai Liu
Jin-Kai Liu
XQXiao-Ye Qu
Xiao-Ye Qu
CSChuan Shen
Chuan Shen
JCJie Cao
Jie Cao
Liver cancer stem cells (LCSCs) are critical drivers of metastasis and chemoresistance in hepatocellular carcinoma (HCC). Proline-rich tyrosine kinase 2 (Pyk2) has been implicated in tumor progression, but its role in LCSC stemness and HCC malignancy remains unclear. This study explores the effects of Pyk2 and its regulation by miR-23b-3p on LCSC function and HCC progression. LCSCs were enriched from HepG2 and HCCLM3 cell lines, and Pyk2 knockdown was induced through siRNA transfection, with or without miR-23b-3p inhibitor co-transfection. We assessed cell proliferation, sphere formation, migration, invasion, and chemosensitivity. Stemness markers (Nanog, Oct4, Sox2, KLF4, and Bmi1) and Pyk2/Src signaling were analyzed via RT-qPCR, Western blotting, and immunohistochemistry. In vivo, tumor growth and Pyk2/Src expressions were evaluated in a BALB/c mouse xenograft model. Pyk2 expression was significantly elevated in the identified LCSCs compared to the parental HCCs. Pyk2 knockdown significantly suppressed the LCSCs proliferation, sphere formation, migration, invasion, and enhanced chemosensitivity. The expression of stemness markers and miR-23b-3p was significantly inhibited in HCCLM3-LCSCsiPyk2 cells. miR-23b-3p inhibition restored Pyk2 level and Src phosphorylation, reversing the suppressive effects of Pyk2 knockdown. In BALB/c mice, tumor volume, weight, and Pyk2/Src expressions were significantly elevated in HCCLM3-LCSC and HCCLM3-LCSCsiPyk2+miR-23b-3p inhibitor groups comparing to HCCLM3/HCCLM3-LCSCsiPyk2 groups, whereas were even heightened in the HCCLM3-LCSC + miR-23b-3p inhibitor group. Inhibiting Pyk2/Src expression by miR-23b-3p suppressed LCSCs function and aggravated HCC progression. Not applicable.

28 April 2026 in Cells
Verified
Journal Article
Open access
PDF file
BZBohan Zhang
Bohan Zhang
YDYun Deng
Yun Deng
MZMingShan Zhou
MingShan Zhou
JCJunfei Chen
Junfei Chen
JWJiawen Wu
Jiawen Wu
JCJie Cao
Jie Cao
Glypican-3 (GPC3)-targeted chimeric antigen receptor T (CAR-T) cell therapy is a promising approach for hepatocellular carcinoma (HCC), but marked interpatient variability and antigen heterogeneity limit its broader application. Here, we established a patient-derived organoid (PDO)-based platform to functionally evaluate autologous GPC3-targeted CAR-T cell activity in HCC. HCC PDOs preserved key histologic features and heterogeneous GPC3 expression patterns of the original tumors. In co-culture assays, CAR-T cell cytotoxicity was associated with GPC3 expression levels and was accompanied by IFN-γ and IL-2 release, supporting the feasibility of using PDOs for functional assessment of CAR-T cell sensitivity. We further found that matrix conditions strongly influenced organoid architecture, viral transduction, CAR-T cell infiltration, and killing efficiency, with lower Matrigel concentrations providing a more permissive setting for functional assessment. Importantly, in GPC3-low PDOs, pretreatment with the DNA methyltransferase inhibitor 5-azacytidine (5-AZA) reduced DNA methyltransferase 3 alpha (DNMT3A) expression, increased surface GPC3 expression, and significantly enhanced CAR-T-mediated cytotoxicity. Together, these findings provide proof-of-concept evidence supporting the use of HCC PDOs as a patient-derived platform for modeling selected determinants of GPC3-targeted CAR-T cell activity and for exploring combination strategies to improve therapeutic efficacy.

1 January 2025 in World Journal of Emergency Medicine
Verified
Journal Article
Closed access
PDF file
SMSha Meng
Sha Meng
QXQu Xiaoye
Qu Xiaoye
LWLu Wenqing
Lu Wenqing
JCJie Cao
Jie Cao
QXQiang Xia
Qiang Xia

24 March 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MZMingShan Zhou
MingShan Zhou
JCJie Cao
Jie Cao
JCJunfei Chen
Junfei Chen
BZBohan Zhang
Bohan Zhang
JWJiawen Wu
Jiawen Wu
MZMin Zhou
Min Zhou
Bcakground: Hepatocellular carcinoma (HCC) is a prevalent malignancy with limited therapeutic options. Drug repurposing offers an attractive strategy to accelerate anticancer discovery. The pleuromutilin class of antibiotics, including the human-approved agent lefamulin and the veterinary drug tiamulin, has shown preliminary anticancer potential, but its efficacy and mechanism in HCC remain unexplored. Methods: The anti-tumor effects of lefamulin and tiamulin were evaluated in HCC cell lines, patient-derived organoids, and a C57BL/6 mouse subcutaneous tumor model. Safety was assessed in a human normal hepatocyte cell line and by histopathological examination of major organs in treated mice. Mechanistic investigations were performed using RNA-sequencing, RT-qPCR, immunohistochemistry (IHC), filipin staining, pharmacological rescue assays, and shRNA-mediated gene silencing. Results: In this study, we found that both lefamulin and tiamulin markedly inhibited HCC cell proliferation in vitro and significantly suppressed tumor growth in vivo (lefamulin vs. control, p = 0.014; tiamulin vs. control, p = 0.021), without causing significant toxicity. RNA-sequencing analysis revealed consistent downregulation of the cholesterol transporter Abca1 (ATP-binding cassette transporter A1) and alterations in cell adhesion molecule pathways. Functional studies confirmed that treatment reduced ABCA1 protein levels, leading to intracellular cholesterol accumulation and aberrant distribution. Furthermore, treated tumors exhibited a significant increase in CD8+ T-cell infiltration, with CD4+ T cells and macrophage infiltration remained unchanged, indicating a specific modulation of the tumor immune microenvironment. Conclusions: These findings suggest that lefamulin and tiamulin are promising therapeutic candidates for HCC.